drug
BMS-986497
Phase 1updated 5mo agoby Bristol-Myers Squibb Co
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying BMS-986497
News(2)
- BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.fiercebiotech · 15d ago
- Bristol Myers scraps $100M Orum-partnered cancer drugBristol Myers Squibb has ended development of a twist on the popular antibody-drug conjugate field. The Phase 1 asset that was axed is BMS-986497/ORM-6151, according to a Thursday regulatory filing…endpoints · 16d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that